TAKEDA PHARMACEUTIC-SP ADR (TAK)
US8740602052 - ADR
ChartMill assigns a Buy % Consensus number of 73% to TAK. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 16.05. This target is 21.38% above the current price.
TAK was analyzed by 23 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about TAK.
In the previous month the buy percentage consensus was at a similar level.
TAK was analyzed by 23 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-05-16 | TD Cowen | Maintains | Outperform -> Outperform |
| 2023-04-04 | TD Cowen | Maintains | Outperform |
| 2023-03-16 | B of A Securities | Upgrade | Neutral -> Buy |
| 2022-07-19 | Cowen & Co. | Upgrade | Market Perform -> Outperform |
| 2021-10-07 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |